Expert Answers in HER2+ Gastroesophageal Adenocarcinoma – with Dr. Jaffer A. Ajani
Advances in HER2-targeted therapies have transformed the treatment landscape for HER2+ gastroesophageal adenocarcinoma (GEA), giving patients more options than ever before. Hear a perspective from gastrointestinal oncologist Dr. Jaffer A. Ajani.
“We are getting a better understanding of the tumor environment…and there’s something very unique about HER2.”
Why HER2 Remains an Important Target in GEA
As part of our Expert Answers in HER2+ Gastroesophageal Adenocarcinoma series, leading specialists share practical insights to help patients and caregivers better understand the unique characteristics of HER2+ GEA, and how it may be treated.
In this installment, Dr. Jaffer A. Ajani, Gastrointestinal Oncologist at MD Anderson Cancer Center, discusses:
- How HER2-targeted therapies have improved outcomes for patients
- Why HER2 continues to be an important target throughout a patient’s treatment journey
- How ongoing research is creating opportunities to further improve care
Explore more Expert Answers in HER2+ Gastroesophageal Adenocarcinoma:
- Yelena Janjigian, MD, Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center
- Manish Shah, MD, Gastrointestinal Oncologist at NewYork-Presbyterian/Weill Cornell Medical Center
